

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A method for the treatment of inflammatory arthritis (IA) in a human subject, comprising:
_____ orally administering to an individual in need of such treatment an effective amount of an active agent consisting of ~~N⁶~~N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA;

wherein the effective amount is an amount which is less than ~~a total daily dose of about 114-70~~ microgram/Kg.

2-4 (Cancelled)

5 (Original). A method of Claim 1, wherein the active agent is administered once a day at a dose of less than about 5 mg.

6 (Currently Amended). A method of Claim 1, wherein the active agent is administered twice a day ~~at a dose of less than about 57 microgram/Kg each dose.~~

7 (Cancelled)

8 (Currently Amended). A method for the treatment of inflammatory arthritis (IA) in a human subject, comprising orally administering to an individual in need of such treatment an effective amount of N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA), wherein the

Appln. No. 10/715,823

Amdt. dated April 24, 2006

Supplemental Reply to Office action of December 22, 2005

effective amount is ~~an amount which is the human equivalent of~~
~~a murine dose of 0.001 mg/Kg to 0.4 mg/Kg~~ a dose of about 0.1
to 1.5 mg administered once or twice per day.

9-28 (Cancelled)